title: 5-Azadeoxycytidine-induced chromatin remodeling of the inactive X-linked HPRT gene promoter occurs prior to transcription factor binding and gene reactivation.
abstract: During the process of 5-aza-2'-deoxycytidine (5aCdr)-induced reactivation of the X-linked human hypoxanthine phosphoribosyltransferase (HPRT) gene on the inactive X chromosome, acquisition of a nuclease-sensitive chromatin conformation in the 5' region occurs before the appearance of HPRT mRNA. In vivo footprinting experiments reported here show that the 5aCdr-induced change in HPRT chromatin structure precedes the appearance of three footprints in the immediate 5' flanking region that are characteristic of the active HPRT allele. These and other data suggest the following sequence of events that lead to the reactivation of the HPRT gene after 5aCdr treatment: (a) hemi-demethylation of the promoter, (b) an "opening" of chromatin structure detectable as increased nuclease sensitivity, (c) transcription factor binding to the promoter, (d) assembly of the transcription complex, and (e) synthesis of HPRT RNA. This sequence of events supports the view that inactive X-linked genes are silenced by a repressive chromatin structure that prevents the binding of transcriptional activators to the promoter.
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Florida College of Medicine, Gainesville, Florida 32610, USA.
authors.forename: M D
authors.initials: MD
authors.lastname: Litt
authors.forename: R S
authors.initials: RS
authors.lastname: Hansen
authors.forename: I K
authors.initials: IK
authors.lastname: Hornstra
authors.forename: S M
authors.initials: SM
authors.lastname: Gartler
authors.forename: T P
authors.initials: TP
authors.lastname: Yang
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002460:Cell Line; D002843:Chromatin / Q000187:drug effects* / Q000648:ultrastructure; D006224:Cricetinae; D000077209:Decitabine; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D006801:Humans; D006822:Hybrid Cells; D007041:Hypoxanthine Phosphoribosyltransferase / Q000096:biosynthesis* / Q000235:genetics*; D007700:Kinetics; D008297:Male; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000096:biosynthesis; D015183:Restriction Mapping; D014157:Transcription Factors / Q000378:metabolism*; D014158:Transcription, Genetic; D014960:X Chromosome
chemical_list: D000964:Antimetabolites, Antineoplastic; D002843:Chromatin; D012333:RNA, Messenger; D014157:Transcription Factors; D000077209:Decitabine; D007041:Hypoxanthine Phosphoribosyltransferase; D001374:Azacitidine